Combined Novel Tumour-targeted Molecular And Traditional Chemotherapy For Treating Androgen Refractory Prostate Cancer
Funder
National Health and Medical Research Council
Funding Amount
$551,398.00
Summary
Consistent with Cancer Australia and PCFA priorities, in preclinical studies we will evaluate triple therapy for advanced prostate cancer.The three treatments to be tested together are adenoviruses, gene therapy and docetaxel, each of which has therapeutic potential individually. The combination should increase therapeutic effiacy and decrease the doses required, thus reducing side effects and increasing quality of life. Results obtained should enable translation to a clinical trial.